230 related articles for article (PubMed ID: 18829553)
1. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S
Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553
[TBL] [Abstract][Full Text] [Related]
2. Triptolide enhances TRAIL sensitivity of pancreatic cancer cells by activating autophagy via downregulation of PUM1.
Dai H; Jiang Y; Luo Y; Bie P; Chen Z
Phytomedicine; 2019 Sep; 62():152953. PubMed ID: 31128486
[TBL] [Abstract][Full Text] [Related]
3. Dual Antagonist of cIAP/XIAP ASTX660 Sensitizes HPV
Xiao R; An Y; Ye W; Derakhshan A; Cheng H; Yang X; Allen C; Chen Z; Schmitt NC; Van Waes C
Clin Cancer Res; 2019 Nov; 25(21):6463-6474. PubMed ID: 31266830
[TBL] [Abstract][Full Text] [Related]
4. Hydroxychavicol sensitizes imatinib-resistant chronic myelogenous leukemia cells to TRAIL-induced apoptosis by ROS-mediated IAP downregulation.
Paul T; Banerjee A; Reddy SVB; Mahato SK; Biswas N
Anticancer Drugs; 2019 Feb; 30(2):167-178. PubMed ID: 30418193
[TBL] [Abstract][Full Text] [Related]
5. Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors.
Phillips DC; Buchanan FG; Cheng D; Solomon LR; Xiao Y; Xue J; Tahir SK; Smith ML; Zhang H; Widomski D; Abraham VC; Xu N; Liu Z; Zhou L; DiGiammarino E; Lu X; Rudra-Ganguly N; Trela B; Morgan-Lappe SE
Cancer Res; 2021 Jun; 81(12):3402-3414. PubMed ID: 33687950
[TBL] [Abstract][Full Text] [Related]
6. Improved Anticancer Effect of Recombinant Protein izTRAIL Combined with Sorafenib and Peptide iRGD.
Fadeev R; Chekanov A; Solovieva M; Bezborodova O; Nemtsova E; Dolgikh N; Fadeeva I; Senotov A; Kobyakova M; Evstratova Y; Yakubovskaya R; Akatov V
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30691192
[TBL] [Abstract][Full Text] [Related]
7. Marine Actinomycetes-Derived Secondary Metabolites Overcome TRAIL-Resistance via the Intrinsic Pathway through Downregulation of Survivin and XIAP.
Elmallah MIY; Cogo S; Constantinescu AA; Elifio-Esposito S; Abdelfattah MS; Micheau O
Cells; 2020 Jul; 9(8):. PubMed ID: 32708048
[TBL] [Abstract][Full Text] [Related]
8. Moracin D suppresses cell growth and induces apoptosis via targeting the XIAP/PARP1 axis in pancreatic cancer.
Zhong X; Ke X; Yang H; Ye X; Li C; Pan J; Ran W; Wang F; Cui H
Phytomedicine; 2024 Jun; 128():155527. PubMed ID: 38489888
[TBL] [Abstract][Full Text] [Related]
9. Mechanism and therapeutic prospect of resveratrol combined with TRAIL in the treatment of renal cell carcinoma.
Zeng Y; Li FD; Shi CW; Du JL; Xue YJ; Liu XY; Cao X; Wei N
Cancer Gene Ther; 2020 Aug; 27(7-8):619-623. PubMed ID: 31664166
[TBL] [Abstract][Full Text] [Related]
10. Noninvasive molecular imaging sheds light on the synergy between 5-fluorouracil and TRAIL/Apo2L for cancer therapy.
Lee KC; Hamstra DA; Bhojani MS; Khan AP; Ross BD; Rehemtulla A
Clin Cancer Res; 2007 Mar; 13(6):1839-46. PubMed ID: 17363540
[TBL] [Abstract][Full Text] [Related]
11. Luteolin-regulated MicroRNA-301-3p Targets Caspase-8 and Modulates TRAIL Sensitivity in PANC-1 Cells.
Moeng S; Son SW; Seo HA; Lee JS; Kim CK; Kuh HJ; Park JK
Anticancer Res; 2020 Feb; 40(2):723-731. PubMed ID: 32014914
[TBL] [Abstract][Full Text] [Related]
12. HOXB9 Overexpression Confers Chemoresistance to Ovarian Cancer Cells by Inducing ERCC-1, MRP-2, and XIAP.
Suh DH; Park WH; Kim M; Kim K; No JH; Kim YB
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674764
[TBL] [Abstract][Full Text] [Related]
13. [Antitumor Activity of TRAIL-Mu3 Protein
Yang T; Zhu AJ; Wang JS; Jin Z
Sichuan Da Xue Xue Bao Yi Xue Ban; 2020 May; 51(3):304-311. PubMed ID: 32543134
[TBL] [Abstract][Full Text] [Related]
14. MADD silencing enhances anti-tumor activity of TRAIL in anaplastic thyroid cancer.
Saini S; Sripada L; Tulla K; Qiao G; Kunda N; Maker AV; Prabhakar BS
Endocr Relat Cancer; 2019 Jun; 26(6):551-563. PubMed ID: 30999276
[TBL] [Abstract][Full Text] [Related]
15. Heightened JNK Activation and Reduced XIAP Levels Promote TRAIL and Sunitinib-Mediated Apoptosis in Colon Cancer Models.
Mahalingam D; Carew JS; Espitia CM; Cool RH; Giles FJ; de Jong S; Nawrocki ST
Cancers (Basel); 2019 Jun; 11(7):. PubMed ID: 31248045
[TBL] [Abstract][Full Text] [Related]
16. Targeting X chromosome-linked inhibitor of apoptosis protein in mucoepidermoid carcinoma of the head and neck: A novel therapeutic strategy using nitidine chloride.
Kwon HJ; Yoon K; Jung JY; Ryu MH; Kim SH; Yoo ES; Choi SY; Yang IH; Hong SD; Shin JA; Cho SD
J Mol Med (Berl); 2020 Nov; 98(11):1591-1602. PubMed ID: 32901343
[TBL] [Abstract][Full Text] [Related]
17. Novel engineered TRAIL-based chimeric protein strongly inhibits tumor growth and bypasses TRAIL resistance.
Rozga P; Kloska D; Pawlak S; Teska-Kaminska M; Galazka M; Bukato K; Pieczykolan A; Jaworski A; Molga-Kaczmarska A; Kopacz A; Badyra B; Kachamakova-Trojanowska N; Zolnierkiewicz O; Targosz-Korecka M; Poleszak K; Szymanik M; Zerek B; Pieczykolan J; Jozkowicz A; Grochot-Przeczek A
Int J Cancer; 2020 Aug; 147(4):1117-1130. PubMed ID: 31863596
[TBL] [Abstract][Full Text] [Related]
18. Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo.
Jhaveri AV; Zhou L; Ralff MD; Lee YS; Navaraj A; Carneiro BA; Safran H; Prabhu VV; Ross EA; Lee S; El-Deiry WS
Cancer Biol Ther; 2021 Dec; 22(10-12):607-618. PubMed ID: 34856854
[TBL] [Abstract][Full Text] [Related]
19. [
Li RH; Yue C; Wei BB; Liu J; Liu H
Sichuan Da Xue Xue Bao Yi Xue Ban; 2020 May; 51(3):320-324. PubMed ID: 32543136
[TBL] [Abstract][Full Text] [Related]
20. Ceramide Analog 5cc Overcomes TRAIL Resistance by Enhancing JNK Activation and Repressing XIAP Expression in Metastatic Colon Cancer Cells.
Huang Q; Liu F
Chemotherapy; 2023; 68(4):210-218. PubMed ID: 37429260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
